Baker Bros. Advisors LP Akero Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,097,082 shares of AKRO stock, worth $41.3 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
1,097,082
Previous 1,097,082
-0.0%
Holding current value
$41.3 Million
Previous $31.5 Million
3.03%
% of portfolio
0.34%
Previous 0.34%
Shares
5 transactions
Others Institutions Holding AKRO
# of Institutions
208Shares Held
66.9MCall Options Held
321KPut Options Held
558K-
Rtw Investments, LP New York, NY6.86MShares$258 Million3.11% of portfolio
-
Janus Henderson Group PLC London, X06.03MShares$227 Million0.09% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$210 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$197 Million5.21% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.32MShares$163 Million0.01% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.75B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...